There are more than 7,000 known rare diseases worldwide, yet only about 5% have an approved treatment. For millions of patients and families, that gap represents more than a statistic. It represents limited options, delayed diagnoses, and years of uncertainty.
The traditional pharmaceutical model is not designed for rare diseases. Drug discovery is expensive, time consuming, and high risk. When patient populations are small, many conditions are left behind, not because they lack urgency, but because they lack economic scale.
That is where Healx is changing the equation.
Founded in Cambridge, UK by David Brown, co inventor of Viagra, and Tim Guilliams, Healx is a clinical stage biotech company using Generative AI to rethink how rare disease treatments are discovered.
A Smarter Approach: Redevelopment Over Reinvention
Instead of starting from scratch, Healx focuses on redevelopment, repurposing existing, known safe compounds and identifying new therapeutic applications for rare diseases.
By leveraging its AI driven Healnet platform, the company can:
- Analyze vast biomedical datasets
- Identify promising drug disease matches
- Accelerate clinical timelines
- Reduce development costs
- Improve probability of success
This approach ensures that no drug’s potential is wasted and that patients are not left waiting decades for innovation.
Recent Milestones
Healx continues to build meaningful clinical and regulatory momentum.
FDA Fast Track Progress
HLX-1502 received Orphan Drug and Rare Pediatric Disease designations for Neurofibromatosis Type 1, NF1.
Clinical Advancement
The FDA cleared Healx’s IND application, enabling HLX-1502 to advance into Phase 2 clinical trials.
Strategic Partnerships
Healx is collaborating with global pharmaceutical leader Sanofi to explore new rare disease indications using the Healnet platform, validating both the science and the AI driven model.
Why This Matters
Rare diseases collectively affect hundreds of millions of people worldwide. While each individual condition may impact a smaller population, together they represent one of the largest unmet needs in global healthcare.
AI powered drug redevelopment has the potential to:
- Shorten timelines from discovery to treatment
- Reduce capital intensity
- Improve capital efficiency for biotech investors
- Deliver meaningful patient impact at scale
At Propel(x), we back companies operating at the intersection of deep technology and real world impact. Healx represents what happens when cutting edge AI meets a relentless commitment to underserved patients.
If you are interested in accessing opportunities in breakthrough biotech, AI driven healthcare, and other frontier technologies, explore private market investments at propelx.com.
